GLP-1 receptor agonists and dual-receptor agonists like semaglutide and tirzepatide have shifted obesity treatment from lifestyle-only approaches to effective pharmacological interventions, with substantial weight loss outcomes and ongoing development of next-generation molecules.
Paradigm shift from lifestyle-only to pharmacological obesity treatmentGLP-1 receptor agonists have demonstrated substantial weight loss outcomes that have fundamentally changed how clinicians approach obesity management
What the researchers found
Semaglutide and tirzepatide have demonstrated weight loss outcomes that have fundamentally shifted the obesity treatment paradigm. These incretin-based therapies work by modulating GLP-1 (and in tirzepatide's case, also GIP) receptor pathways, leading to decreased caloric intake through appetite suppression.
The review notes that benefits extend beyond weight loss to include metabolic improvements, though challenges remain around long-term efficacy (weight regain after discontinuation), tolerability (gastrointestinal side effects), and accessibility (cost and supply constraints). Future directions include combination therapies and novel molecules with dual or triple receptor activity targeting GLP-1, GIP, and glucagon receptors simultaneously.
Why it matters
Obesity affects over 1 billion people worldwide and drives cardiovascular disease, type 2 diabetes, and numerous other conditions. Until recently, pharmacological options for obesity were limited and modestly effective. The GLP-1 receptor agonist class has changed this dramatically, producing weight loss of 15-20% or more — approaching what was previously only achievable with bariatric surgery. This review helps clinicians navigate the practical aspects of prescribing these medications.
How the study worked
This is a narrative clinical review that synthesizes published clinical trial data and guidelines on the use of GLP-1 receptor agonists (liraglutide, semaglutide) and dual GLP-1/GIP receptor agonists (tirzepatide) for obesity management. It focuses on practical clinical application rather than basic science.
What this study cannot tell us
As a narrative review, this article synthesizes existing evidence rather than presenting new data. The review acknowledges but may not fully quantify several key limitations of incretin therapy: weight regain after discontinuation, long-term safety beyond available trial durations, gastrointestinal tolerability, cost barriers ($1,000+ per month without insurance coverage in many settings), and supply chain constraints that have limited access. The review does not address potential concerns about muscle mass loss during rapid weight reduction.
How to read the evidence
This is a narrative clinical review synthesizing data from multiple randomized controlled trials and clinical experience. While the underlying evidence base is strong (large RCTs for each drug), the review itself is an expert synthesis, not a systematic review or meta-analysis.
When this study was published
Published in 2026, this is an extremely current review reflecting the latest state of incretin therapy for obesity, including the newest approved agents and emerging pipeline molecules.
The bigger picture
The incretin therapy revolution represents one of the most significant developments in medicine in the past decade. What began as diabetes drugs has transformed into a new treatment paradigm for obesity, with potential applications expanding to cardiovascular protection, kidney disease, liver disease, and possibly neurodegeneration. The success of these peptide-based drugs has also driven unprecedented pharmaceutical investment in next-generation molecules, including oral formulations, longer-acting versions, and multi-receptor agonists like retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors).
Questions still open
- How can weight regain after discontinuation of GLP-1 therapy be prevented — through maintenance doses, lifestyle intervention, or combination approaches?
- Will triple-receptor agonists provide meaningfully better weight loss than current dual-receptor agonists, and at what cost to tolerability?
- How should clinicians prioritize among the available incretin therapies given cost, insurance coverage, and individual patient factors?
Common questions
What's the difference between semaglutide and tirzepatide for weight loss?
Do you regain weight when you stop taking these medications?
Read the original research
Current clinical application of incretin therapy for obesity management.
Canadian journal of physiology and pharmacology, 104, 1-8
Citation
Skinner, Karlie; Clements, Jennifer N. (2026). Current clinical application of incretin therapy for obesity management.. Canadian journal of physiology and pharmacology, 104, 1-8. https://doi.org/10.1139/cjpp-2025-0152